Eleven Biotherapeutics Appoints Paul Chaney To Its Board Of Directors

Published: Mar 03, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company’s board of directors.

Help employers find you! Check out all the jobs and post your resume.

Back to news